Effect of Mivazerol on Perioperative Cardiac Complications during Non-cardiac Surgery in Patients with Coronary Heart Disease

Abstract

The alpha2-adrenergic agonist, mivazerol, did not alter the rates of myocardial infarction or cardiac death in patients with known coronary heart disease undergoing noncardiac surgery. However, it may have protected patients undergoing vascular surgery from further coronary events, and a specific study of such patients is now indicated.